Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. It is not yet known which dose of imatinib mesylate is more
effective in treating gastrointestinal stromal tumor.
PURPOSE: This randomized phase III trial is studying two different doses of imatinib mesylate
to compare how well they work in treating patients with unresectable or metastatic
gastrointestinal stromal tumor.
Phase:
Phase 3
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators:
Australasian Gastro-Intestinal Trials Group Italian Sarcoma Group Scandinavian Sarcoma Group